4 D Molecular Therapeutics Inc (FDMT)

Dec 11, 2025

4D Molecular Therapeutics expands phase 3 trial enrollment - MSN

Dec 11, 2025

Dec 10, 2025

4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks

Dec 10, 2025

Dec 08, 2025

4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Dec 08, 2025

Dec 08, 2025

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Dec 08, 2025

Dec 05, 2025

4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN

Dec 05, 2025

Dec 04, 2025

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat

Dec 04, 2025

Dec 02, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat

Dec 02, 2025

Dec 02, 2025

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN

Dec 02, 2025

Dec 01, 2025

4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN

Dec 01, 2025

Nov 26, 2025

How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockGlobal Markets & Safe Capital Investment Plans - BỘ NỘI VỤ

Nov 26, 2025

Nov 26, 2025

4D Molecular Therapeutics taps Kristian Humer as CFO - MSN

Nov 26, 2025

Nov 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2025

Nov 23, 2025

4D Molecular Therapeutics Appoints New Financial Officer - MSN

Nov 23, 2025

Nov 21, 2025

Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - marketscreener.com

Nov 21, 2025

Nov 21, 2025

FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Nov 21, 2025

Nov 20, 2025

Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat

Nov 20, 2025

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat

Nov 20, 2025

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan

Nov 20, 2025

Nov 19, 2025

4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada

Nov 19, 2025

Nov 19, 2025

[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

Nov 19, 2025

4D Molecular Therapeutics Executive Sells Shares - TradingView

Nov 19, 2025

Nov 19, 2025

Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView

Nov 19, 2025

Nov 19, 2025

Published on: 2025-11-19 17:30:27 - newser.com

Nov 19, 2025

Nov 18, 2025

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Nov 18, 2025

Nov 18, 2025

4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN

Nov 18, 2025

Nov 18, 2025

What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com

Nov 18, 2025

Nov 18, 2025

FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView

Nov 18, 2025

Nov 18, 2025

FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView

Nov 18, 2025

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Appoints New Chief Financial Officer - TipRanks

Nov 17, 2025

Nov 17, 2025

4D Molecular (FDMT) Therapeutics Appoints New CFO to Drive Finan - GuruFocus

Nov 17, 2025

Nov 17, 2025

4DMT Appoints Kristian Humer as Chief Financial Officer - The Globe and Mail

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Appoints New CFO - TradingView

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer | FDMT Stock News - Quiver Quantitative

Nov 17, 2025

Nov 17, 2025

[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan

Nov 17, 2025

Nov 17, 2025

4D Molecular Therapeutics (Nasdaq: FDMT) names Kristian Humer CFO to lead finance - Stock Titan

Nov 17, 2025

Nov 16, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat

Nov 16, 2025

Nov 15, 2025

4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 15, 2025

Nov 15, 2025

FY2025 Earnings Forecast for FDMT Issued By Chardan Capital - MarketBeat

Nov 15, 2025

Nov 14, 2025

Can 4D Molecular Therapeutics Inc. rally from current levelsMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com

Nov 14, 2025

Nov 14, 2025

4DMT Announces New Employment Inducement Grants - Enidnews.com

Nov 14, 2025

Nov 14, 2025

4DMT (NASDAQ: FDMT) grants 45,400 RSUs to four new employees under 2025 inducement plan - Stock Titan

Nov 14, 2025

Nov 14, 2025

Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings - MarketBeat

Nov 14, 2025

Nov 12, 2025

Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position - TipRanks

Nov 12, 2025

Nov 12, 2025

Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st

Nov 12, 2025

Nov 11, 2025

Barclays Maintains 4D Molecular Therapeutics (FDMT) Overweight Recommendation - Nasdaq

Nov 11, 2025

Nov 11, 2025

4D Molecular Therapeutics Misses On Revenue But Secures New Funding - Finimize

Nov 11, 2025

Nov 11, 2025

Working capital per share of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView

Nov 11, 2025

Nov 11, 2025

4D Molecular Therapeutics: Financial Backing Strengthens Clinical Pipeline Prospects - Ad-hoc-news.de

Nov 11, 2025